https://scholars.lib.ntu.edu.tw/handle/123456789/512431
標題: | Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior? | 作者: | Chang C.-H. Lee C.-H. JANN-YUAN WANG |
公開日期: | 2017 | 出版社: | American Society of Clinical Oncology | 卷: | 35 | 期: | 12 | 起(迄)頁: | 1374 | 來源出版物: | Journal of Clinical Oncology | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017648983&doi=10.1200%2fJCO.2016.68.5842&partnerID=40&md5=bf416f9851f31ac9954cdbdd3e8343a5 https://scholars.lib.ntu.edu.tw/handle/123456789/512431 |
ISSN: | 0732-183X | DOI: | 10.1200/JCO.2016.68.5842 | SDG/關鍵字: | epidermal growth factor receptor; erlotinib; gefitinib; erlotinib; gefitinib; quinazoline derivative; cancer chemotherapy; cancer patient; cancer recurrence; cancer staging; cancer survival; comparative effectiveness; drug efficacy; gene mutation; human; Letter; lung adenocarcinoma; maximum tolerated dose; overall survival; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; progression free survival; randomized controlled trial (topic); treatment duration; lung adenocarcinoma; lung tumor; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。